Work Here?
Crinetics Pharmaceuticals
Work Here?
Clinical-stage pharma developing rare endocrine therapies
Crinetics Pharmaceuticals
Work Here?
Clinical-stage pharma developing rare endocrine therapies
Overview
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare endocrine diseases and endocrine-related tumors. Its work centers on creating novel orally administered treatments, with CRN00808 for acromegaly currently in Phase 2 trials. The product approach involves identifying targets in endocrine pathways (often GPCRs), and engineering oral drug candidates that modulate these targets to treat conditions with few existing options. The company differentiates itself by concentrating on rare endocrine disorders and advancing candidates through clinical development, aiming to secure regulatory approvals and then pursue commercialization, often via partnerships or licensing with larger pharma players. Its goal is to provide effective, targeted therapies for patients with unmet endocrine needs and to bring approved medicines to market through disciplined clinical development and external collaborations.
About Crinetics Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
2008
Get referred to Crinetics Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $25.1 million, with $24.0 million from PALSONIFY sales.
- June 2026 cash totaled $1.2 billion, funding atumelnant through Phase 3.
- FDA granted atumelnant Rare Pediatric Disease Designation in 2026.
What critics are saying
- Standalone Crinetics ended September 1, 2026; Vertex controls strategy, staffing, and site footprints.
- PALSONIFY sales still need rapid payer conversion beyond early 2026 launch momentum.
- Atumelnant remains phase 3 dependent; a safety miss would erase the $10 billion thesis.
What makes Crinetics Pharmaceuticals unique
- PALSONIFY became FDA-approved September 2025, the first once-daily oral acromegaly therapy.
- Crinetics built oral GPCR endocrinology chemistry, spanning somatostatin and ACTH antagonism.
- Vertex bought Crinetics on September 1, 2026 for $10 billion.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.5B
Above
Industry Average
Funded Over
10 Rounds
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Unlimited Paid Time Off
PTO/vacation
Holiday/Vacation not?
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 2%Crinetics Pharmaceuticals discloses GLP-1R agonists. Sep. 1, 2026 Work at Crinetics Pharmaceuticals Inc. has led to the identification of new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity.
Crinetics Pharmaceuticals (NASDAQ:CRNX) hits new 52-week high after better-than-expected earnings. August 4, 2026 Key points. * Crinetics Pharmaceuticals shares reached a new 52-week high of $84 after the company reported quarterly EPS of -$1.14, beating estimates of -$1.18, while revenue of $25.12 million surpassed the $14.84 million consensus and rose 2,336.9% year over year. * Analyst sentiment is mixed, with a consensus "Hold" rating from five Buy, 11 Hold and one Sell ratings; the average price target is $81, while UBS raised its target to $85. * Institutional investors own 98.51% of the stock, with major holders including Wellington Management and Farallon Capital increasing their positions; two directors recently sold shares under pre-arranged trading plans. * MarketBeat previews the top five stocks to own by September 1st. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $84.00 and last traded at $83.95, with a volume of 799004 shares changing hands. The stock had previously closed at $83.76. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.04. Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The firm had revenue of $25.12 million during the quarter, compared to analyst estimates of $14.84 million. During the same period in the previous year, the business posted ($1.23) earnings per share. The business's revenue for the quarter was up 2336.9% on a year-over-year basis. Analysts set new price targets. A number of equities research analysts have weighed in on the stock. Lifesci Capital lowered shares of Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. UBS Group reiterated a "neutral" rating and set a $85.00 price objective (up from $55.00) on shares of Crinetics Pharmaceuticals in a research report on Tuesday, July 28th. Citizens Jmp cut Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research report on Friday, July 17th. Finally, Piper Sandler cut shares of Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $81.00. Insider buying and selling. In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the sale, the director owned 6,400 shares in the company, valued at approximately $228,288. This trade represents a 51.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the transaction, the director directly owned 19,225 shares in the company, valued at $769,000. This represents a 13.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company's stock. Institutional trading of Crinetics Pharmaceuticals. Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Crinetics Pharmaceuticals by 44.3% in the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company's stock worth $349,110,000 after buying an additional 2,574,683 shares during the period. Farallon Capital Management LLC raised its holdings in Crinetics Pharmaceuticals by 20.2% during the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company's stock valued at $322,736,000 after acquiring an additional 1,163,000 shares during the period. Janus Henderson Group PLC lifted its position in shares of Crinetics Pharmaceuticals by 1.8% in the first quarter. Janus Henderson Group PLC now owns 4,520,251 shares of the company's stock valued at $164,227,000 after acquiring an additional 79,560 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in shares of Crinetics Pharmaceuticals by 8.8% in the third quarter. Paradigm Biocapital Advisors LP now owns 2,550,774 shares of the company's stock valued at $106,240,000 after acquiring an additional 207,221 shares in the last quarter. Finally, Siren L.L.C. boosted its stake in shares of Crinetics Pharmaceuticals by 26.3% in the first quarter. Siren L.L.C. now owns 1,903,636 shares of the company's stock worth $69,140,000 after acquiring an additional 396,000 shares during the period. 98.51% of the stock is currently owned by institutional investors. Crinetics Pharmaceuticals price performance. The firm has a 50-day moving average of $55.09 and a 200-day moving average of $46.39. The stock has a market cap of $8.85 billion, a PE ratio of -16.37 and a beta of 0.12. About Crinetics Pharmaceuticals. Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence. The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Crinetics Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list. While Crinetics Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Vertex was sole bidder in high-premium Crinetics acquisition. Analysts expect new details on the lead-up to the deal "are likely to reignite" investor scrutiny that Vertex overpaid in what's poised to be its largest-ever transaction. Published July 22, 2026 Vertex Pharmaceuticals was the lone bidder in a planned, $10 billion acquisition that has some investors questioning whether the biotechnology giant overpaid on its largest-ever deal. Financial documents filed Tuesday provide an inside look at the tie-up between Vertex and Crinetics Pharmaceuticals, a California-based company specializing in endocrine drugs. Crinetics has one marketed therapy for an uncommon hormonal condition, as well as an experimental medicine in late-stage testing for a rare genetic disease called congenital adrenal hyperplasia. Vertex estimates that, together, the two drugs could generate north of $5 billion a year at their peak. Yet, at a 102% premium, the $85-per-share offer is one of the biggest markups this year for a biotech buyout, according to BioPharma Dive data. When Vertex shares dipped after the deal's announcement, analysts suspected that investors weren't happy with the price tag. The deal value "assumes a bullish case outcome" for Crinetics' drugs, and will likely stir debates about whether Vertex "paid full price or even a rich price," Stifel analyst Paul Matteis wrote in a July 6 note to clients. The newly released documents "are likely to reignite" that investor scrutiny, according to RBC Capital Markets analyst Brian Abrahams. The seeds for the acquisition, like many biopharma deals, were planted at the industry's annual bellwether event: the J.P. Morgan Healthcare Conference. Crinetics' filings describe how, during that mid-January conference, its own representatives met with Vertex's external innovation team "as part of ordinary course business development activity." A couple months passed before Vertex, on March 14, reached out to Crinetics' CEO R. Scott Struthers about a potential transaction. By March 24, Vertex submitted a proposal to buy all of the biotech's outstanding shares for $78 apiece, reflecting a 125% premium to the stock's most recent closing price. Crinetics quickly tapped Leerink Partners and J.P. Morgan to serve as financial advisors, and, together, this team spent the next 10 days evaluating the proposal. Crinetics' board of directors acknowledged the sizable premium, but believed that, since this was an initial offer, Vertex would be willing to go higher. On April 5, the board rejected the bid but cleared Struthers to tell Vertex they may reconsider if terms were "significantly improved." On April 19, Vertex revised its offer to $83 per share, which, by that time, represented a 102% premium. But it still didn't pass muster. Crinetics' board members knocked down the new proposal three days later. And, with adviser help, they came up with a list of six other companies that might be interested in - and have the resources to finance - a substantial transaction. In the final week of April, three of those six counterparties conveyed they didn't want to make a deal. Another, "Party A," did express interest. By May 1, however, it determined it couldn't propose a transaction worth north of $6 billion. After some back and forth, "Party A" dropped out of the deal process. The final two contenders followed suit the next week. From May 8-28, Crinetics and Vertex continued to exchange due diligence information. On that latter date, Vertex upped its offer to $84.50 per share, or a 130% premium. The Crinetics board concluded that, because this new offer would be dilutive to Vertex's earnings per share in the near term, it was likely at or near the maximum Vertex would be willing to pay. Still, the board wanted to see if it could squeeze out a little more, so they relayed a counterproposal of $87 per share. Vertex representatives said further due diligence was required before they could put forward a final offer. On June 19, a senior representative contacted Struthers and said Vertex was prepared to buy Crinetics for $85 per share. Crinetics tried to eke out one more dollar per share, but Vertex responded that the $85 price point was its best and final offer. Crinetics' board found this acceptable, and after squaring away other final concerns, the companies reached an agreement on July 6.
Shareholder alert: Ademi LLP investigates whether Crinetics pharmaceuticals, inc. is obtaining a fair price for public shareholders. July 21, 2026 07:37 ET | Source: Ademi LLP MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) - Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Crinetics by imposing a significant penalty if Crinetics accepts a competing bid. We are investigating the conduct of the Crinetics board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discove...
Crinetics Pharmaceuticals is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Crinetics Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
2008
Crinetics Pharmaceuticals is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today